N. Morelli (Den Haag, Netherlands), D. Halpin (Exeter, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Worsening of gas exchange parameters at high FiO2 in COVID-19: misleading or informative?
F. Raimondi (Bergamo, Italy), L. Novelli (Bergamo, Italy), G. Marchesi (Bergamo, Italy), I. Riva (Bergamo, Italy), L. Grazioli (Bergamo, Italy), C. Allegri (Bergamo, Italy), R. Biza (Bergamo, Italy), R. Trapasso (Bergamo, Italy), M. Amoroso (Bergamo, Italy), M. Anelli (Bergamo, Italy), C. Galimberti (Milan, Italy), F. Fabretti (Bergamo, Italy), F. Lorini (Bergamo, Italy), F. Di Marco (Bergamo, Italy)
|    |
Do hospitalized COVID-19 patients have endothelial vascular dysfunction? A cohort study
M. OLIVEIRA (São Carlos, Brazil), G. Back (São Carlos, Brazil), C. Goulart (São Carlos, Brazil), B. Domingos (São Carlos, Brazil), R. Arena (Chicago, United States of America), A. Borghi-Silva (São Carlos, Brazil)
| |
Inhibition by umifenovir is broadly effective against coronaviruses
I. LENEVA (Moscow, Russian Federation), E. Faizuloev (Moscow, Russian Federation), N. Kartashova (Moscow, Russian Federation), A. Gracheva (Moscow, Russian Federation), E. Korchevaya (Moscow, Russian Federation), A. Poromov (Moscow, Russian Federation), G. Ignatyev (Moscow Region, Russian Federation), V. Volok (Moscow Region, Russian Federation), L. Kozlovskaya (Moscow Region, Russian Federation), S. Loginova (Moscow, Russian Federation), V. Shchukina (Moscow, Russian Federation), R. Khamitov (Vladimir Region,Volginsky, Russian Federation)
| |
Experience of using Janus kinase inhibitors in COVID-19
T. Luchnikova (Blagoveshchensk (Amur Oblast), Russian Federation), O. Prikhodko (Blagoveshchensk (Amur Oblast), Russian Federation), K. Fesyun (Khabarovsk, Russian Federation)
| |
Predictors of negative first SARS-CoV-2 PCR despite final diagnosis of COVID-19 and association with outcome
J. Lascarrou (Nantes, France), G. Colin (La Roche-sur-Yon, France), A. Le Thuaut (Nantes, France), N. Serck (Ottignies, Belgium), M. Ohana (Strasbourg, France), B. Sauneuf (Cherbourg-en-Cotentin, France), G. Geri (Boulogne Billancourt, France), J. Mesland (Jolimont, Belgium), G. Ribeyre (Avignon, France), C. Hussenet (Nantes, France), A. Boureau (Nantes, France), T. Gille (Bobigny, France)
| |
COVID19: a retrospective cohort study in Bradford with a focus on ethnicity
L. Smith (Bradford (West Yorkshire), United Kingdom), N. Pattabhiraman (Bradford (West Yorkshire), United Kingdom), G. Appleyard (Bradford (West Yorkshire), United Kingdom), I. Hutchesson (Bradford (West Yorkshire), United Kingdom), K. Jackson (Bradford (West Yorkshire), United Kingdom), S. Wadanamby (Bradford (West Yorkshire), United Kingdom), A. Lister (Bradford (West Yorkshire), United Kingdom), J. Bhatti (Bradford (West Yorkshire), United Kingdom), S. Hemphill (Bradford (West Yorkshire), United Kingdom), K. Poterlowicz (Bradford (West Yorkshire), United Kingdom), D. Saralaya (Bradford (West Yorkshire), United Kingdom)
| |
Validation of the CFS score in patients with Covid-19 receiving only ward based care
K. Jackson (Newcastle, United Kingdom), E. Edwards (Newcastle, United Kingdom), E. Marsh (Newcastle, United Kingdom), C. Moores (Newcastle, United Kingdom), E. Longden (Newcastle, United Kingdom), P. Chinedu (Newcastle, United Kingdom), M. Ingram (Newcastle, United Kingdom), G. Stonier (Newcastle, United Kingdom), E. Tullo (Newcastle, United Kingdom), L. Mackay (Newcastle, United Kingdom), C. Dotchin (Newcastle, United Kingdom), A. Hussain (Newcastle, United Kingdom), S. Dale (Newcastle, United Kingdom), S. Manning (Newcastle, United Kingdom), L. Dew (Newcastle, United Kingdom), T. Ross (Newcastle, United Kingdom), L. Wannous (Newcastle, United Kingdom), S. Oxenburgh (Newcastle, United Kingdom), D. Murphy (Newcastle, United Kingdom), R. Gavin (Newcastle, United Kingdom), L. Taylor (Newcastle, United Kingdom), S. Welsh (Newcastle, United Kingdom), C. Carolan (Newcastle, United Kingdom), A. Donne (Newcastle, United Kingdom), N. Moss (Newcastle, United Kingdom), J. Gwinnell (Newcastle, United Kingdom), F. Starkie (Newcastle, United Kingdom), R. Johnston (Newcastle, United Kingdom), J. Dundas (Newcastle, United Kingdom), J. Jones (Newcastle, United Kingdom), K. Davies (Newcastle, United Kingdom), R. Anderson (Newcastle, United Kingdom), P. Ireland (Newcastle, United Kingdom), A. Aujayeb (Newcastle, United Kingdom)
| |
High pulse dose steroids in Severe COVID-19 pneumonitis refractory hypoxemia to dexamethasone
N. Khalil (Oranjestad, Aruba), J. Kileci (Oranjestad, Aruba), S. Kock (Oranjestad, Aruba)
| |
Late Breaking Abstract - Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof of concept clinical trial
I. Gyselinck (Leuven, Belgium), R. Vos (Leuven, Belgium), L. Liesenborghs (Leuven, Belgium), P. Verhamme (Leuven, Belgium), W. Janssens (Leuven, Belgium)
| |
Discussion
| |